Navigation Links
Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
Date:3/22/2011

CAMBRIDGE, Mass., March 22, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that researchers will present pre-clinical data related to PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, at a late-breaking oral presentation at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida.

PVS-30200, which utilizes Pervasis' proprietary implantable material comprised of healthy allogeneic (donor) endothelial cells embedded in a polymer matrix, is designed to be administered locally to regulate processes involved in tumor growth and metastasis, including cell-proliferation, inflammation and invasion, in order to prevent the spread of cancer to secondary sites in the body. The well-studied patented technology on which PVS-30200 is founded has a proven safety profile as demonstrated by data from six clinical studies in the area of vascular repair.

Joseph Franses, from the Massachusetts Institute of Technology's (MIT) Division of Health Sciences and Technology, is the lead author of the abstract titled, "A first-in-class novel therapy (PVS-30200) for the treatment and prevention of metastatic cancer by regulating the tumor microenvironment," and will present the data at a Late-Breaking Research Session on Cancer Therapeutics and Epidemiology beginning at 3:00 p.m. on Tuesday, April 5, 2011 in Room W415 B/C (Vallencia Ballroom) at the Orange County Convention Center.

"We look forward to presenting PVS-30200 data at AACR and to having an opportunity to communicate the potential for this therapy to the oncology community," said Helen Marie Nugent, PhD, Co-Founder and Vice President, Research and Development at Pervasis and a co-author of the AACR abstract. "We are moving forward aggressively with our development program for PVS-30200 in order to deliver a safer, more effective treatment for solid tumors, preventing cancer recurrence and improvi
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
5. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
6. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... 2011 iAdvantage Software, Inc. , ... life science studies, today announced that BioTox Sciences ... San Diego, California, is deploying the eStudy™ ... preclinical/nonclinical studies . (Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO) ...
... Reportlinker.com announces that a new market research ... Cancer Vaccines - Pipeline Assessment and Market ... Cancer Vaccines - Pipeline Assessment ... SummaryGlobalData, the industry analysis specialist,s new report, "Cancer ...
Cached Medicine Technology:BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 2BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 3Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... who drink more than 15 drinks of alcohol a ... like anxiety disorder and depression. ,Researchers of University ... the study said that there is a significant link ... research study has been the largest longitudinal study in ...
... Health, US, have found out //that almost 50% of the ... early as the teenage and may remain undetected for a ... in spite of efficient treatments available, patients stay untreated for ... disorders once diagnosed, difficult to treat as they become more ...
... Gold nanoparticles may be used to detect cancer, says a ... ,The father and son research team had been able ... cells, a process that will make the tracing of cancer ... called epidermal growth factor receptor (EFGR) over their surface. This ...
... screening of the mouth by trained health workers can help ... the oral cancer mortality rate. ,A research done by ... possible to visually screen people for oral cancer in order ... of oral cancer patients. ,Oral cancer is the growth ...
... women take is affected by factors like stress, mood, //anxiety ... the American Dietetic Association. ,Diet in pregnancy is very ... contain the food elements like folic acid and other vitamins ... women who are more often exhausted or stressed tend to ...
... cancer may have higher risks of having cognitive// impairment ... of Southern California had found that patients who survived ... as much risk as their healthy counterparts of having ... of cancer and their twins with the help of ...
Cached Medicine News:
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
... for applications such as vasectomy that ... ,The autoclavable handpiece with six-foot cord ... cautery electrodes, allowing the physician to ... wide variety of procedures., ,The 2201 ...
No Scalpel Vasectomy Hemostat 5 1/2" (14cm), smooth sharp point, curved, gold finger rings...
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company....
Medicine Products: